In contrast to GLP-1, which is used with success for the treatment of type 2 diabetes (T2DM) and obesity, GIP receptor (GIPR)–based agonism alone produces limited biological and pharmacological effects (9, 10). Here, GLP1R is linked to obesity disorder.